Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Non-Current Assets (2016 - 2025)

Agios Pharmaceuticals (AGIO) has disclosed Non-Current Assets for 13 consecutive years, with $355.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non-Current Assets fell 49.09% year-over-year to $355.2 million, compared with a TTM value of $1.7 billion through Dec 2025, changed 0.24%, and an annual FY2025 reading of $355.2 million, down 49.09% over the prior year.
  • Non-Current Assets was $355.2 million for Q4 2025 at Agios Pharmaceuticals, up from $352.6 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $717.6 million in Q3 2024 and bottomed at $103.3 million in Q4 2023.
  • Average Non-Current Assets over 5 years is $358.2 million, with a median of $359.6 million recorded in 2023.
  • The sharpest move saw Non-Current Assets crashed 74.56% in 2023, then skyrocketed 575.42% in 2024.
  • Year by year, Non-Current Assets stood at $373.5 million in 2021, then grew by 8.69% to $405.9 million in 2022, then crashed by 74.56% to $103.3 million in 2023, then surged by 575.42% to $697.6 million in 2024, then plummeted by 49.09% to $355.2 million in 2025.
  • Business Quant data shows Non-Current Assets for AGIO at $355.2 million in Q4 2025, $352.6 million in Q3 2025, and $451.8 million in Q2 2025.